Skip to main content

A Phase 1/1b first-in-human dose escalation and expansion study for theevaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination with REGN2810 in adult

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Sanofi US

Start Date

January 18, 2019

End Date

February 7, 2024
 

Administered By

Duke Cancer Institute

Awarded By

Sanofi US

Start Date

January 18, 2019

End Date

February 7, 2024